GO:0032900 negative regulation of neurotrophin production: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032900 describes any biological process that stops, prevents, or reduces the production of a neurotrophin, a family of secreted growth factors critical for neuronal survival, development, and plasticity.
• Neurotrophin production is controlled at multiple levels, including transcription, mRNA stability, and post-translational processing, and negative regulation can occur at any of these steps.
• Key neurotrophins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), whose dysregulation is linked to neurodegenerative and inflammatory diseases.
• Negative regulators such as microRNAs (e.g., miR-129) and transcription factors can suppress neurotrophin production, influencing axonal regeneration and disease progression.
• Dysregulation of neurotrophin production is implicated in Alzheimer's disease, osteoarthritis, and peripheral nerve injury, making this GO term a target for therapeutic intervention.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of negative regulatory mechanisms and validation of candidate genes in neurotrophin production pathways.
Description
Neurotrophins are a family of secreted proteins that regulate neuronal survival, differentiation, and synaptic plasticity. The production of neurotrophins is tightly controlled to maintain nervous system homeostasis, and its dysregulation contributes to a range of neurological and inflammatory disorders. GO:0032900, negative regulation of neurotrophin production, captures the biological processes that reduce the frequency, rate, or extent of neurotrophin synthesis. Understanding these negative regulatory mechanisms is essential for researchers studying neurodevelopment, neurodegeneration, and regenerative medicine. This article provides a comprehensive overview of the ontology, key genes, molecular mechanisms, disease associations, and experimental approaches for studying negative regulation of neurotrophin production.
negative regulation of neurotrophin production At A Glance
| GO ID | GO:0032900 |
|---|---|
| GO term | negative regulation of neurotrophin production |
| Ontology | biological_process |
| Synonym | down regulation of neurotrophin production, down-regulation of neurotrophin production, downregulation of neurotrophin production, inhibition of neurotrophin production |
| Major function | Suppression of neurotrophin synthesis, processing, or secretion |
| Related processes | Regulation of neurotrophin production, neurotrophin signaling, neuronal survival |
| Cellular location | Nucleus, cytoplasm, secretory pathway (varies by mechanism) |
| Key regulators | Transcription factors, microRNAs, signaling pathways (e.g., CART, inhibins) |
| Disease relevance | Alzheimer's disease, osteoarthritis, peripheral nerve injury |
What Is GO:0032900?
According to the Gene Ontology, GO:0032900 (negative regulation of neurotrophin production) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of a neurotrophin. This term encompasses molecular events that suppress the synthesis, processing, or release of neurotrophic factors such as NGF, BDNF, NT-3, and NT-4. It is a biological process that can act at transcriptional, post-transcriptional, or post-translational levels to limit neurotrophin availability.
Why Is negative regulation of neurotrophin production Important in Cell Biology?
Negative regulation of neurotrophin production is critical for preventing excessive neurotrophic signaling, which can lead to aberrant neuronal growth, inflammation, or tumorigenesis. Conversely, insufficient negative regulation may contribute to neurodegenerative conditions where neurotrophin levels are dysregulated. Understanding this process provides insights into disease mechanisms and identifies potential therapeutic targets for modulating neurotrophin levels in conditions such as Alzheimer's disease, osteoarthritis, and nerve injury.
• Maintains homeostatic levels of neurotrophins to prevent overstimulation of neuronal growth.
• Dysregulation is linked to Alzheimer's disease, where BDNF production is altered.
• In osteoarthritis, NGF production by macrophages is regulated by negative feedback mechanisms.
• MicroRNAs such as miR-129 negatively regulate IGF-1, affecting axonal regeneration after nerve injury.
• Negative regulators like CART and inhibins modulate granulosa cell estradiol production, indicating broader roles in endocrine tissues.
• Provides targets for therapeutic intervention in neurodegenerative and inflammatory diseases.
• Essential for proper nervous system development and plasticity.
• Can be studied using CRISPR knockout and overexpression models to identify causal genes.
• Relevant to cancer biology, as neurotrophins can promote tumor growth and survival.
• Helps explain variability in neurotrophin levels across tissues and disease states.
What Happens During negative regulation of neurotrophin production?
Transcriptional repression of neurotrophin genes
In simple terms: This step reduces the amount of mRNA made from neurotrophin genes.
Negative regulation often begins with transcriptional repression of genes encoding neurotrophins such as BDNF or NGF. Transcription factors and co-repressors bind to promoter or enhancer regions, reducing RNA polymerase II recruitment. For example, non-canonical transcriptional regulation of the BDNF gene involves complex promoter usage and repressor elements that can downregulate production. In inflammatory conditions, cytokines can suppress BDNF transcription, contributing to reduced neurotrophic support.
Post-transcriptional control by microRNAs
In simple terms: Small RNAs can bind to neurotrophin mRNAs and prevent them from being translated.
MicroRNAs (miRNAs) negatively regulate neurotrophin production by base-pairing with complementary sequences in the 3' untranslated region of target mRNAs, leading to translational repression or degradation. For instance, miR-129 controls axonal regeneration by regulating insulin-like growth factor-1 (IGF-1), a neurotrophic factor, in peripheral nerve injury. This illustrates how miRNAs can act as negative regulators of neurotrophic support.
Regulation of neurotrophin processing and secretion
In simple terms: Even if mRNA is made, the protein may not be processed or released.
Neurotrophins are synthesized as precursors (pro-neurotrophins) that undergo proteolytic cleavage to mature forms. Negative regulation can occur by inhibiting convertases or by retaining precursors intracellularly. In macrophages from osteoarthritic synovium, NGF production is regulated at the level of secretion, with negative feedback mechanisms limiting its release. Similarly, CART and inhibins can negatively regulate granulosa cell estradiol production, indicating that secretory pathways are subject to negative control.
Feedback inhibition by neurotrophin signaling
In simple terms: Activation of neurotrophin receptors can trigger signals that shut down further production.
Neurotrophin binding to Trk receptors activates downstream signaling cascades (e.g., MAPK, PI3K) that can feedback to inhibit transcription of the neurotrophin gene itself. This negative feedback loop prevents excessive neurotrophic stimulation. In Alzheimer's disease, inflammation-associated neurogenesis involves BDNF as a mediator, and dysregulated feedback may contribute to pathology. Such feedback mechanisms are essential for maintaining homeostasis.
Extracellular sequestration and clearance
In simple terms: Neurotrophins can be bound or degraded outside the cell, reducing their effective concentration.
Negative regulation also includes extracellular mechanisms that limit neurotrophin availability. Binding proteins, such as low molecular weight insulin-like growth factor binding proteins, can sequester neurotrophic factors and reduce their activity. Additionally, proteolytic degradation by extracellular proteases can clear neurotrophins from the extracellular space. These mechanisms ensure that neurotrophin levels are tightly controlled in tissues.
Key Genes Involved in GO:0032900 negative regulation of neurotrophin production
The following genes and proteins are involved in negative regulation of neurotrophin production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BDNF | Neurotrophin; its production is negatively regulated at transcriptional and post-transcriptional levels | Studied in Alzheimer's disease, neurogenesis, and synaptic plasticity |
| NGF | Neurotrophin; production is regulated in inflammatory and arthritic conditions | Target in osteoarthritis and pain research |
| miR-129 | MicroRNA that negatively regulates IGF-1, affecting axonal regeneration | Peripheral nerve injury models |
| IGF-1 | Neurotrophic factor; its production is negatively regulated by miR-129 | Axonal regeneration and nerve repair |
| CART | Negative regulator of granulosa cell estradiol production; may influence neurotrophin-like factors | Endocrine regulation and follicular waves |
| INHBA | Inhibin subunit; negative regulator of estradiol production | Reproductive biology and potential neurotrophin cross-talk |
| IGFBP | Insulin-like growth factor binding proteins; sequester IGFs | Modulation of neurotrophic factor availability |
| DBI | Diazepam-binding inhibitor; negative regulator of saliva secretion | Potential role in neurotrophin regulation in salivary glands |
| TrkB | BDNF receptor; mediates feedback inhibition | Neurotrophin signaling and feedback |
| TrkA | NGF receptor; mediates feedback inhibition | NGF signaling and regulation |
| p75NTR | Neurotrophin receptor; can mediate negative regulation | Apoptosis and neurotrophin modulation |
| NF-κB | Transcription factor; can repress BDNF transcription in inflammation | Alzheimer's disease and neuroinflammation |
| CREB | Transcription factor; regulates BDNF expression; can be negatively regulated | Neuroplasticity and memory |
| MECP2 | Transcriptional repressor; may regulate BDNF expression | Rett syndrome and neurodevelopmental disorders |
| GCG | Glucagon; may influence neurotrophic factor production | Metabolic regulation |
| INS | Insulin; can modulate neurotrophic signaling | Metabolic and neurodegenerative research |
| VEGFA | Angiogenic factor; negative regulators of angiogenesis may cross-regulate neurotrophins | Exudative AMD and vascular biology |
| HIF1A | Hypoxia-inducible factor; can regulate neurotrophin production under hypoxia | Ischemia and neurodegeneration |
How Is negative regulation of neurotrophin production Regulated?
Negative regulation of neurotrophin production is itself controlled by various signaling pathways. For example, inflammatory cytokines can activate NF-κB, which represses BDNF transcription. MicroRNAs such as miR-129 provide post-transcriptional control. Hormonal signals, including inhibins and CART, negatively regulate estradiol production in granulosa cells, suggesting similar mechanisms may operate in neurotrophin-producing cells. Additionally, feedback from neurotrophin receptors (TrkA, TrkB) can suppress further production. These regulatory layers ensure tight control of neurotrophin levels.
negative regulation of neurotrophin production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BDNF | Alzheimer's disease; reduced neurotrophic support | Knockout or knockdown in neuronal cell lines; overexpression of negative regulators |
| NGF | Osteoarthritis; pain and inflammation | Macrophage cell models with CRISPR knockout of negative regulators |
| miR-129 | Peripheral nerve injury; impaired axonal regeneration | miR-129 knockout or overexpression in dorsal root ganglion neurons |
| IGF-1 | Neurotrophic support; regulated by miR-129 | Knock-in of miR-129 binding site mutations |
| VEGFA | Exudative AMD; angiogenesis | Endothelial cell models with neurotrophin regulators |
Alzheimer's disease
In Alzheimer's disease, BDNF production is often reduced, and inflammatory mediators can exacerbate this decline by negatively regulating BDNF transcription. Dysregulation of negative regulatory mechanisms may contribute to synaptic loss and cognitive decline. Understanding how BDNF production is suppressed could lead to therapies that restore neurotrophic support.
Osteoarthritis
NGF is a key mediator of pain in osteoarthritis, and its production by macrophages in synovium is subject to negative regulation. Excessive NGF contributes to pain, while insufficient negative regulation may worsen symptoms. Targeting negative regulators of NGF production could provide analgesic strategies.
Peripheral nerve injury
After peripheral nerve injury, axonal regeneration depends on neurotrophic factors like IGF-1. miR-129 negatively regulates IGF-1, and its downregulation promotes regeneration. Modulating negative regulators of neurotrophin production may enhance nerve repair.
Exudative age-related macular degeneration (AMD)
Negative regulators of angiogenesis are important targets in AMD, and neurotrophins can influence vascular biology. Although direct links are less established, cross-talk between neurotrophin and angiogenic pathways may be relevant.
From negative regulation of neurotrophin production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate BDNF production? | CRISPR knockout of gene X in neuroblastoma cells, followed by BDNF ELISA |
| What is the effect of a point mutation in a transcription factor on neurotrophin repression? | Point mutation knock-in using CRISPR in iPSC-derived neurons |
| Can overexpression of a microRNA reduce NGF levels? | Lentiviral overexpression of miR-129 in macrophage cell lines |
| How does a tagged negative regulator localize in cells? | Knock-in of GFP tag on candidate gene in neuronal cells |
| Which genes are essential for negative regulation of neurotrophin production? | Genome-wide CRISPR library screening in neurotrophin reporter cells |
| Does a disease-associated SNP affect neurotrophin production? | Knock-in of SNP using CRISPR in patient-derived cells |
How to Study the negative regulation of neurotrophin production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of neurotrophins and regulators | Transcriptional repression studies |
| ELISA | Secreted neurotrophin protein | Quantifying NGF or BDNF production |
| Western blot | Intracellular neurotrophin precursors and mature forms | Processing and cleavage analysis |
| Luciferase reporter assay | MicroRNA-mediated repression | Validating miR-129 targeting of IGF-1 |
| CRISPR knockout screening | Genes affecting neurotrophin production | Discovery of negative regulators |
| Immunofluorescence | Localization of neurotrophins and regulators | Tissue-specific expression patterns |
| qPCR | Relative mRNA expression | Rapid validation of transcriptional changes |
Transcriptional profiling (RNA-seq)
RNA sequencing can quantify mRNA levels of neurotrophins and their negative regulators under different conditions. This method identifies transcriptional changes that reduce neurotrophin production, such as repression of BDNF or NGF genes.
Protein quantification (ELISA, Western blot)
ELISA and Western blot measure mature neurotrophin protein levels, revealing post-transcriptional and post-translational negative regulation. For example, NGF secretion from macrophages can be quantified by ELISA.
MicroRNA target validation (luciferase reporter assays)
Luciferase reporters containing the 3' UTR of neurotrophin genes can confirm direct negative regulation by microRNAs such as miR-129.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects neurotrophin production, providing unbiased discovery of negative regulators.
How CRISPR Can Be Used to Study GO:0032900 negative regulation of neurotrophin production
Knockout
CRISPR knockout of candidate negative regulators can be used to test whether their loss increases neurotrophin production. For example, knocking out a microRNA like miR-129 would be expected to elevate IGF-1 levels, confirming its negative regulatory role. This approach is powerful for identifying causal genes in neurotrophin regulation.
Point Mutation
Point mutations can be introduced into transcription factor binding sites or microRNA seed regions to disrupt negative regulation. For instance, mutating a repressor binding site in the BDNF promoter could increase BDNF production, helping to map regulatory elements.
Knock-in
Knock-in of reporter genes (e.g., luciferase or GFP) under the control of neurotrophin promoters allows real-time monitoring of negative regulation. Additionally, tagging endogenous negative regulators with epitope tags facilitates their study.
Overexpression
Overexpression of a suspected negative regulator, such as a microRNA or repressor protein, can suppress neurotrophin production. This is useful for validating negative regulatory activity and for screening potential therapeutic targets.
How EDITGENE Supports negative regulation of neurotrophin production Research
Researchers studying negative regulation of neurotrophin production-related genes often need to determine whether a candidate gene is causally involved in suppressing neurotrophin synthesis. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of neurotrophin production research.
Frequently Asked Questions About negative regulation of neurotrophin production
What is GO:0032900?
GO:0032900 is the Gene Ontology term for negative regulation of neurotrophin production, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of neurotrophin production.
What genes are involved in negative regulation of neurotrophin production?
Key genes include BDNF, NGF, miR-129, IGF-1, CART, and inhibins, among others.
How is neurotrophin production negatively regulated?
It can be regulated at transcriptional, post-transcriptional, and post-translational levels, including microRNA-mediated repression and feedback inhibition.
What diseases are associated with dysregulation of neurotrophin production?
Alzheimer's disease, osteoarthritis, and peripheral nerve injury are linked to altered neurotrophin regulation.
What is the role of BDNF in negative regulation of neurotrophin production?
BDNF is a neurotrophin whose production is subject to negative regulation; its dysregulation is implicated in Alzheimer's disease.
How can CRISPR be used to study negative regulation of neurotrophin production?
CRISPR knockout, knock-in, and overexpression models allow functional validation of candidate negative regulators in neurotrophin-producing cells.
What are the synonyms for GO:0032900?
Synonyms include down regulation of neurotrophin production, down-regulation of neurotrophin production, downregulation of neurotrophin production, and inhibition of neurotrophin production.
Which microRNAs negatively regulate neurotrophin production?
miR-129 negatively regulates IGF-1, a neurotrophic factor, in peripheral nerve injury.
What experimental models are used to study negative regulation of neurotrophin production?
Common models include neuronal cell lines, iPSC-derived neurons, and macrophage cultures, often with CRISPR modifications.
Why is negative regulation of neurotrophin production important?
It prevents excessive neurotrophic signaling and maintains homeostasis; its dysregulation contributes to neurodegenerative and inflammatory diseases.
Conclusion
Negative regulation of neurotrophin production (GO:0032900) is a critical biological process that controls the availability of neurotrophic factors. Dysregulation of this process is linked to major human diseases, including Alzheimer's disease, osteoarthritis, and peripheral nerve injury. Advances in CRISPR-based models and high-throughput screening are enabling researchers to identify and characterize the genes and pathways involved. EDITGENE provides comprehensive services to support these investigations, from knockout to overexpression and bioinformatics analysis.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Kobayashi Y et al.. 2006. Evidence of a local negative role for cocaine and amphetamine regulated transcript (CART), inhibins and low molecular weight insulin like growth factor binding proteins in regulation of granulosa cell estradiol production during follicular waves in cattle.. Reprod Biol Endocrinol 4:22 PMID: 16611367
- 3. Farnoodian M et al.. 2017. Negative regulators of angiogenesis: important targets for treatment of exudative AMD.. Clin Sci (Lond) 131(15):1763-1780 PMID: 28679845
- 4. Tsukagoshi E et al.. 2011. Diazepam enhances production of diazepam-binding inhibitor (DBI), a negative saliva secretion regulator, localized in rat salivary gland.. J Pharmacol Sci 115(2):221-9 PMID: 21282931
- 5. Keifer J. 2021. Comparative Genomics of the BDNF Gene, Non-Canonical Modes of Transcriptional Regulation, and Neurological Disease.. Mol Neurobiol 58(6):2851-2861 PMID: 33517560
- 6. Chen JJ et al.. 2016. Brain-derived neurotrophic factor: a mediator of inflammation-associated neurogenesis in Alzheimer's disease.. Rev Neurosci 27(8):793-811 PMID: 27508959
- 7. Takano S et al.. 2017. Nerve growth factor regulation and production by macrophages in osteoarthritic synovium.. Clin Exp Immunol 190(2):235-243 PMID: 28677145
- 8. Zhu H et al.. 2018. miR-129 controls axonal regeneration via regulating insulin-like growth factor-1 in peripheral nerve injury.. Cell Death Dis 9(7):720 PMID: 29915198
